Thymosin Beta-4 used for TBI and Post Stroke Patients

By Dr. Hannah 15 days agoTraumatic Brain Injury (TBI) is an injury to the brain caused by an external force such as a blow to the head, a fall, a car accident, or a sudden jolt. The extent of the injury can range from mild (concussion) to severe (coma or even death) and can result in physical, cognitive, and emotional difficulties. TBI is a leading cause of death and disability worldwide, affecting millions of people of all ages and socioeconomic backgrounds.

Stroke, on the other hand, occurs when blood flow to the brain is disrupted, leading to brain cell death and potential long-term damage. This can happen due to a blocked blood vessel (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). Strokes can cause a range of physical and cognitive symptoms, such as weakness or paralysis on one side of the body, difficulty speaking or communicating, and memory loss.

The impact of TBI and stroke on our health and society is profound. According to the Centers for Disease Control and Prevention (CDC), TBI contributed to over 2.8 million emergency department visits, hospitalizations, and deaths in the United States in 2014 alone. Stroke is also a leading cause of death and disability, with nearly 800,000 people in the United States experiencing a stroke each year, and approximately 140,000 deaths from stroke annually.

In terms of the economic impact, TBI and stroke are estimated to cost the U.S. economy billions of dollars each year in medical expenses and lost productivity. In addition to the financial burden, TBI and stroke can also have a significant emotional impact on the individual, their families, and their communities.

These statistics highlight the importance of increased awareness, research, and support for individuals affected by TBI and stroke. With proper care and support, however, many individuals can recover and lead fulfilling lives.

Thymosin Beta 4 Review

Thymosin Beta 4 (TB4) is a naturally occurring peptide that is widely distributed in various tissues and organs of the human body. It is a small protein composed of 43 amino acids and is involved in several physiological processes, including cell migration, proliferation, and survival.

The mechanism of action by which TB4 works is not fully understood, but it is believed to play a role in regulating the activities of cells involved in tissue repair and regeneration. TB4 has been shown to promote the migration and proliferation of various cell types, including stem cells, and to enhance their ability to differentiate into specific cell types and integrate into damaged tissues.

In addition to its role in tissue repair, TB4 has been shown to have anti-inflammatory and anti-apoptotic effects, meaning that it can help reduce inflammation and prevent cell death in various diseases and conditions. For example, TB4 has been shown to improve outcomes in animal models of stroke, heart attack, and liver injury, and is currently being investigated as a potential treatment for a range of human diseases, including wound healing, neurological disorders, and cardiovascular disease.

While the precise mechanisms by which TB4 works are still being studied, its ability to promote cell migration, proliferation, and survival, as well as to reduce inflammation and prevent cell death, make it a promising target for future research and therapeutic development.

Furthermore, TB4 has been investigated as a potential treatment for TBI and stroke due to its ability to promote cell migration, proliferation, and survival, as well as to reduce inflammation and prevent cell death. Studies in animal models of TBI have shown that TB4 can reduce the extent of brain damage and improve functional outcomes. For example, a study published in the journal "Brain Research" found that administration of TB4 following TBI in rats resulted in a significant reduction in brain edema (swelling), a reduction in the number of dead brain cells, and improved behavioral outcomes compared to control animals. Another study published in the "Journal of Neurotrauma" found that TB4 treatment improved the migration and differentiation of neural stem cells in the brain, which may contribute to the repair of damaged tissues and the improvement of functional outcomes following TBI.

Similarly, studies in animal models of stroke have shown that TB4 can reduce the extent of brain damage and improve functional outcomes. A study published in the "Journal of Stroke and Cerebrovascular Diseases" found that TB4 treatment improved the migration and differentiation of bone marrow-derived stem cells in the brain, which contributed to the reduction of brain damage and improved functional outcomes following stroke. Another study published in the "Journal of Neurochemistry" found that TB4 treatment reduced the levels of pro-inflammatory cytokines and oxidative stress in the brain, which may contribute to the reduction of brain damage and the improvement of functional outcomes following stroke.

Research Example #1

Treatment of traumatic brain injury with thymosin β4 in rats

Object

This study was designed to investigate the efficacy of delayed thymosin β4 (TB4) treatment of traumatic brain injury (TBI) in rats.Methods

Young adult male Wistar rats were divided into the following groups: 1) Sham group (6 rats); 2) TBI + Saline group (9 rats); 3) and TBI + Tβ4 group (10 rats). TBI was induced by controlled cortical impact over the left parietal cortex. Thymosin β4 (6 mg/kg) or saline was administered intraperitoneally starting at Day 1 and then every 3 days for an additional 4 doses. Neurological function was assessed using a modified neurological severity score (mNSS), foot-fault and Morris water maze tests. Animals were killed 35 days after injury, and brain sections stained for immunohistochemistry to assess angiogenesis, neurogenesis, and oligodendrogenesis after Tβ4 treatment.Results

Compared to the saline treatment, delayed Tβ4 treatment did not affect lesion volume but significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, increased oligodendrogenesis in the CA3 region, and significantly improved sensorimotor functional recovery and spatial learning.Conclusions

These data for the first time demonstrate that delayed administration of Tβ4 significantly improves histological and functional outcomes in rats with TBI, indicating that Tβ4 has considerable therapeutic potential for patients with TBI.

Research Example #2Thymosin beta4: a candidate for treatment of stroke?

Neurorestorative therapy is the next frontier in the treatment of stroke. An expanding body of evidence supports the theory that after stroke, certain cellular changes occur that resemble early stages of development. Increased expression of developmental proteins in the area bordering the infarct suggest an active repair or reconditioning response to ischemic injury. Neurorestorative therapy targets parenchymal cells (neurons, oligodendrocytes, astrocytes, and endothelial cells) to enhance endogenous neurogenesis, angiogenesis, axonal sprouting, and synaptogenesis to promote functional recovery. Pharmacological treatments include statins, phosphodiesterase 5 inhibitors, erythropoietin, and nitric oxide donors that have all improved functional outcome after stroke in the preclinical arena. Thymosin beta4 (Tbeta4) is expressed in both the developing and adult brain and it has been shown to stimulate vasculogenesis, angiogenesis, and arteriogenesis in the postnatal and adult murine cardiac myocardium. In this manuscript, we describe our rationale and techniques to test our hypothesis that Thymosin beta4 may be a candidate neurorestorative agent.

Research Example #3

Neuroprotective and neurorestorative effects of Thymosin beta 4 treatment following experimental traumatic brain injury

Traumatic brain injury (TBI) remains a leading cause of mortality and morbidity worldwide. No effective pharmacological treatments are available for TBI because all Phase II/III TBI clinical trials have failed. This highlights a compelling need to develop effective treatments for TBI. Endogenous neuro-restoration occurs in the brain after TBI, including angiogenesis, neurogenesis, synaptogenesis, oligodendrogenesis and axonal remodeling, which may be associated with spontaneous functional recovery after TBI. However, the endogenous neuro-restoration following TBI is limited. Treatments amplifying these neurorestorative processes may promote functional recovery after TBI. Thymosin beta4 (Tβ4) is the major G-actin-sequestering molecule in eukaryotic cells. In addition, Tβ4 has other properties including anti-apoptosis and anti-inflammation, promotion of angiogenesis, wound healing, stem/progenitor cell differentiation, and cell migration and survival, which provide the scientific foundation for the corneal, dermal, and cardiac wound repair multicenter clinical trials. Here, we describe Tβ4 as a neuroprotective and neurorestorative candidate for treatment of TBI.

Research Example #4

Protective effect of Tβ4 on central nervous system tissues and its developmental prospects

---

Tissue repair and regeneration in the central nervous system (CNS) remains a serious medical problem. CNS diseases such as traumatic and neurological brain injuries have a high mortality and disability rate, thereby bringing a considerable amount of economic burden to society and families. How to treat traumatic and neurological brain injuries has always been a serious issue faced by neurosurgeons. The global incidence of traumatic and neurological brain injuries has gradually increased and become a global challenge. Thymosin β4 (Tβ4) is the main G-actin variant molecule in eukaryotic cells. During the development of the CNS, Tβ4 regulates neurogenesis, tangential expansion, tissue growth, and cerebral hemisphere folding. In addition, Tβ4 has anti-apoptotic and anti-inflammatory properties. It promotes angiogenesis, wound healing, stem/progenitor cell differentiation, and other characteristics of cell migration and survival, providing a scientific basis for the repair and regeneration of injured nerve tissue. This review provides evidence to support the role of Tβ4 in the protection and repair of nervous tissue in CNS diseases, especially with the potential to control brain inflammatory processes, and thus open up new therapeutic applications for a series of neurodegenerative diseases.

References